[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1119533T1 - Νεοι θεραπευτικοι παραγοντες - Google Patents

Νεοι θεραπευτικοι παραγοντες

Info

Publication number
CY1119533T1
CY1119533T1 CY20171101145T CY171101145T CY1119533T1 CY 1119533 T1 CY1119533 T1 CY 1119533T1 CY 20171101145 T CY20171101145 T CY 20171101145T CY 171101145 T CY171101145 T CY 171101145T CY 1119533 T1 CY1119533 T1 CY 1119533T1
Authority
CY
Cyprus
Prior art keywords
new therapeutic
therapeutic factors
inhibitors
class
act
Prior art date
Application number
CY20171101145T
Other languages
English (en)
Inventor
Yu Chen
Yi Chen
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1119533T1 publication Critical patent/CY1119533T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μια κατηγορία ενώσεων υδροξαμικού οξέος του Τύπου (I), οι οποίες δρουν ως αλκυλιωτικοί παράγοντες ή/και αναστολείς της οδού HDAC, έχοντας πιθανή χρησιμότητα στη θεραπευτική αγωγή νεοπλασματικής ασθένειας και άνοσων ασθενειών.
CY20171101145T 2012-02-01 2017-11-02 Νεοι θεραπευτικοι παραγοντες CY1119533T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593459P 2012-02-01 2012-02-01
US201261678064P 2012-07-31 2012-07-31
PCT/EP2013/051944 WO2013113838A1 (en) 2012-02-01 2013-01-31 Novel therapeutic agents

Publications (1)

Publication Number Publication Date
CY1119533T1 true CY1119533T1 (el) 2018-03-07

Family

ID=47624111

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101145T CY1119533T1 (el) 2012-02-01 2017-11-02 Νεοι θεραπευτικοι παραγοντες

Country Status (27)

Country Link
US (1) US10118901B2 (el)
EP (1) EP2809657B1 (el)
JP (1) JP6129211B2 (el)
KR (1) KR102127871B1 (el)
CN (1) CN104066722B (el)
AR (1) AR092790A1 (el)
AU (1) AU2013214204B2 (el)
BR (1) BR112014018879B1 (el)
CA (1) CA2863330C (el)
CY (1) CY1119533T1 (el)
DK (1) DK2809657T3 (el)
ES (1) ES2645271T3 (el)
HK (1) HK1203963A1 (el)
HR (1) HRP20171727T1 (el)
HU (1) HUE035194T2 (el)
IL (1) IL233756A (el)
LT (1) LT2809657T (el)
ME (1) ME02914B (el)
MX (1) MX352231B (el)
NZ (1) NZ626618A (el)
PH (1) PH12014501718B1 (el)
PL (1) PL2809657T3 (el)
PT (1) PT2809657T (el)
RS (1) RS56592B1 (el)
SI (1) SI2809657T1 (el)
TW (1) TWI573792B (el)
WO (2) WO2013113838A1 (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009088986A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BR112013017670B1 (pt) 2011-01-10 2022-07-19 Infinity Pharmaceuticals, Inc Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) * 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
EP2819741B1 (en) 2012-02-27 2018-03-28 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
NZ711585A (en) 2013-03-15 2020-05-29 Biomarin Pharm Inc Hdac inhibitors
EP2992086B1 (en) * 2013-04-30 2020-09-30 La Jolla Institute for Allergy and Immunology Modulation of regulatory t cell function via protein kinase c-eta
CN103601682B (zh) * 2013-09-22 2015-07-29 浙江理工大学 3-烯基-1h-吲唑化合物的制备方法
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
CN104086624B (zh) * 2014-03-21 2017-01-18 河南海汇药物研究有限公司 一种卡非佐米的制备方法
KR102456088B1 (ko) 2014-04-04 2022-10-19 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
CZ201584A3 (cs) 2015-02-09 2016-08-17 Zentiva, K.S. Sůl Ibrutinib sulfátu
CR20170420A (es) 2015-03-13 2017-10-03 Forma Therapeutics Inc Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
CN106146501A (zh) * 2015-03-26 2016-11-23 江苏豪森药业集团有限公司 一种无定型激酶抑制剂的制备方法
CN106146500A (zh) * 2015-03-26 2016-11-23 江苏豪森药业集团有限公司 5-氟-3-苯基-2-[(1s)-1-(9h-嘌呤-6-基氨基)丙基]-4(3h)-喹唑啉酮晶型及其制备方法
KR102015826B1 (ko) * 2015-04-21 2019-08-29 구이저우 바이링 그룹 파마슈티컬 컴퍼니 리미티드 퓨리닐-n-하이드록실 피리미딘 포름아미드 유도체, 이의 제조 방법 및 용도
SI3302550T1 (sl) * 2015-05-26 2020-01-31 Morphosys Ag Kombinacija anti-CD19 protitelesa in inhibitorja bruton tirozin kinaze in njihova uporaba
WO2017067474A1 (zh) * 2015-10-20 2017-04-27 杭州民生药物研究院有限公司 一种药物组合物及其制备方法
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
CZ2016196A3 (cs) 2016-04-06 2017-10-18 Zentiva, K.S. Pevné formy Ibrutinibu
CZ2016276A3 (cs) 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
CN107929712A (zh) * 2017-12-12 2018-04-20 中山大学肿瘤防治中心 一种治疗肝癌的联合药物
ES2962605T3 (es) 2018-02-26 2024-03-20 Gilead Sciences Inc Compuestos de pirrolizina sustituidos como inhibidores de la replicación del VHB
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US20200352565A1 (en) * 2019-05-08 2020-11-12 Covidien Lp Surgical stapling device

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD34727A1 (de) 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
EP0986403B1 (en) 1997-06-13 2003-11-12 Cydex Inc. Composition with extended shelf-life storage comprising cyclodextrin and drugs or prodrugs that decompose to water-insoluble components
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US20020076409A1 (en) 2000-07-12 2002-06-20 March Carl J. Method for treating cancer
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
CN1764648A (zh) * 2003-01-13 2006-04-26 安斯泰来制药有限公司 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
JP4790594B2 (ja) 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Hdacインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
CN1787999A (zh) * 2003-03-17 2006-06-14 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
US8227636B2 (en) 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
MX2007013938A (es) 2005-05-13 2008-01-28 Topotarget Uk Ltd Formulaciones farmaceuticas de inhibidores de histona desacetilasa.
WO2008067027A2 (en) 2006-10-20 2008-06-05 Icos Corporation Compositions of chkl inhibitors and cyclodextrin
GB0621160D0 (en) * 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
MX2009005292A (es) 2006-11-20 2009-08-13 Cephalon Inc Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante.
CN101084876A (zh) 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
US20090131367A1 (en) 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
US8987468B2 (en) 2008-02-04 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
CN102164579B (zh) 2008-09-25 2014-10-15 赛福伦公司 苯达莫司汀的液体配制品
WO2010042568A1 (en) 2008-10-08 2010-04-15 Cephalon, Inc. Processes for the preparation of bendamustine
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
ME02254B (me) 2009-01-23 2015-12-31 Euro Celtique Sa Derivati hidroksamske kiseline
WO2010097700A1 (en) 2009-02-25 2010-09-02 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
CN101928234B (zh) 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-(杂)芳基-n-羟基己/庚酰胺化合物及其制备方法
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
CN102993102B (zh) 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n,n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法
EP2758052B9 (en) 2011-09-18 2019-03-27 Euro-Celtique S.A. Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
PT2760860T (pt) 2011-09-28 2017-02-21 Euro Celtique Sa Derivados de mostarda de azoto
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
EP3226903A1 (en) 2014-12-05 2017-10-11 University of Modena and Reggio Emila Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
US20180098969A1 (en) 2016-10-11 2018-04-12 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy

Also Published As

Publication number Publication date
PL2809657T3 (pl) 2018-03-30
CA2863330A1 (en) 2013-08-08
ME02914B (me) 2018-10-20
US10118901B2 (en) 2018-11-06
HUE035194T2 (en) 2018-05-02
LT2809657T (lt) 2017-11-27
HRP20171727T1 (hr) 2017-12-29
MX352231B (es) 2017-11-15
IL233756A (en) 2017-09-28
AU2013214204A1 (en) 2014-07-17
KR20140119721A (ko) 2014-10-10
EP2809657A1 (en) 2014-12-10
BR112014018879B1 (pt) 2022-08-16
CN104066722B (zh) 2017-05-10
AU2013214204B2 (en) 2017-02-16
IL233756A0 (en) 2014-09-30
CN104066722A (zh) 2014-09-24
JP2015505552A (ja) 2015-02-23
JP6129211B2 (ja) 2017-05-17
CA2863330C (en) 2020-10-20
BR112014018879A2 (el) 2017-06-20
WO2013113841A1 (en) 2013-08-08
NZ626618A (en) 2015-09-25
TW201343632A (zh) 2013-11-01
ES2645271T3 (es) 2017-12-04
AR092790A1 (es) 2015-05-06
TWI573792B (zh) 2017-03-11
RS56592B1 (sr) 2018-02-28
WO2013113838A1 (en) 2013-08-08
HK1203963A1 (en) 2015-11-06
PH12014501718A1 (en) 2014-11-10
BR112014018879A8 (pt) 2017-07-11
PH12014501718B1 (en) 2014-11-10
KR102127871B1 (ko) 2020-06-30
SI2809657T1 (en) 2018-01-31
DK2809657T3 (en) 2017-12-11
PT2809657T (pt) 2017-11-28
MX2014009357A (es) 2014-09-12
EP2809657B1 (en) 2017-09-06
US20150086551A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
CY1119533T1 (el) Νεοι θεραπευτικοι παραγοντες
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
CY1118156T1 (el) Ενωσεις αντιστροφης αμιδης ως αναστολεις δεακετυλασης πρωτεϊνων και μεθοδοι χρησης αυτων
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
CY1123056T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
EA201500926A1 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
UA113403C2 (xx) Спосіб підвищення ефективності folr1 терапії раку
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
EA201692271A1 (ru) Терапевтически активные соединения и способы их применения
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201291357A1 (ru) Способы лечения с применением ингибиторов tlr7 и/или tlr9
CY1121825T1 (el) Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
BR112015006705A2 (pt) antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
TR201907241T4 (tr) IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2.